OR WAIT null SECS
Mukkamala discussed other priorities the AMA’s Substance Use and Pain Care Task Force is tackling with OUD.
Last month, the FDA approved the prior supplement submission for Indivior’s buprenorphine extended-release injection (SUBLOCADE) to treat opioid use disorder (OUD) almost 1 year after its initial approval for treating treat moderate to severe OUD.1,2
The new labeling expands the approved subcutaneous injection site of the abdomen to the thigh, buttock, and back of the upper arm for induction and maintenance.1 In another shift, the current 7-day minimum on transmucosal buprenorphine will be amended to a single dose of transmucosal buprenorphine with a 1-hour observation period to confirm tolerability and patients will be allowed to receive a second 300 mg dose 1 week after the initial 300 mg injections.
HCPLive spoke with otolaryngologist Bobby Mukkamala, MD, who is serving as president-elect of the American Medical Association (AMA) and chair of the AMA’s Substance Use and Pain Care Task Force, to learn more about the labeling change. He also shared other priorities in the shifting world of care for OUD.
“We would really encourage folks that are trying to take care of their communities and trying to take care of their patients to look and see what comes from our task force. It's a very useful, but one of many sources of knowledge so we can take better care of our communities and our patients,” Mukkamala said.
Conversations about supporting treatment for OUD are especially pertinent as Congress just a couple of days ago failed to address payment cuts imposed in the CY25 Medicare Physician Fee Schedule (MPFS), comprising care for vulnerable patient populations.
Mukkamala has no relevant disclosures to report.